do compounded glp-1 drugs work GLP-1/GIP Injections Online The Dangers of Using Unapproved

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

[DOI] [PubMed] [Google Scholar] 21.Scott LJ

Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials

Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 12 Dual GIPGLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential Authors Bastin M , Andreelli F Received 12 May 2019 Accepted for publication 17 August 2019 Published 30 September 2019 Volume 2019:12 Pages 19731985 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Konstantinos Tziomalos Marie Bastin, Fabrizio Andreelli Diabetology-Metabolism Department, Sorbonne Universit, ICAN, Assistance Publique Hpitaux de Paris, Piti-Salptrire Hospital, Paris, F-75013, France Correspondence: Fabrizio Andreelli Diabetology-Metabolism Department, Piti-Salptrire Hospital, 47-83 Boulevard de lHpital, Paris cedex 13, 75951, France Email [email protected] Abstract: The need for efficient and safe therapy to improve such metabolic diseases as obesity and type 2 diabetes mellitus is currently unmet

Luciani, P., Fibbi, B., Mazzanti, B., Deledda, C., Ballerini, L., Aldinucci, A., et al

Back Klausen, MK, Jensen, ME, Mller, M, et al (6 Sept 2022) 'Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial', JCI Insight, 7/19, e159863